These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17563252)

  • 21. The management of patients with early Parkinson's disease.
    Rascol O; Brefel-Courbon C; Payoux P; Ferreira J
    Adv Neurol; 2003; 91():203-11. PubMed ID: 12442679
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination pharmacotherapy in unipolar depression.
    Ng F; Dodd S; Berk M
    Expert Rev Neurother; 2006 Jul; 6(7):1049-60. PubMed ID: 16831118
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample.
    Verdoux H; Pambrun E
    Acta Psychiatr Scand; 2014 Dec; 130(6):487-97. PubMed ID: 25302631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing therapeutic effects in patients with comorbidities: drug-resistant tremor, autonomic dysfunction, psychiatric disorders, and cognitive impairment.
    Chitnis S
    Neurol Clin; 2008 Aug; 26(3 Suppl):S29-44, v-vi. PubMed ID: 18774441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral changes as side effects of medication treatment for Parkinson's disease.
    Hui JS; Murdock GA; Chung JS; Lew MF
    Adv Neurol; 2005; 96():114-29. PubMed ID: 16383216
    [No Abstract]   [Full Text] [Related]  

  • 26. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions in the treatment of Parkinson's disease.
    Jost WH; Brück C
    J Neurol; 2002 Oct; 249 Suppl 3():III/24-9. PubMed ID: 12522568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An approach to the psychopharmacologic care of patients: antidepressants, antipsychotics, anxiolytics, mood stabilizers, and natural remedies.
    Huffman JC; Alpert JE
    Med Clin North Am; 2010 Nov; 94(6):1141-60, x. PubMed ID: 20951275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Behavioral disorders in Parkinson's disease. Genetic, pharmacological and medico-legal aspects].
    Sobrido MJ; Dias-Silva JJ; Quintáns B
    Rev Neurol; 2009 Jan; 48 Suppl 1():S43-8. PubMed ID: 19222015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Utilization of psychopharmaceuticals in Norwegian psychiatric hospitals 1991-2000].
    Rytter E; Håberg M
    Tidsskr Nor Laegeforen; 2003 Mar; 123(6):768-71. PubMed ID: 12693110
    [No Abstract]   [Full Text] [Related]  

  • 33. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease--Part 2: Treatment of motor symptoms.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case studies in the advancement of Parkinson's disease.
    Frei K; Truong DD; Wolters E
    CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Punding in Parkinson's disease.
    O'Sullivan SS; Evans AH; Lees AJ
    Pract Neurol; 2007 Nov; 7(6):397-9. PubMed ID: 18024780
    [No Abstract]   [Full Text] [Related]  

  • 38. Abuse of psychopharmacological drugs--experiences in Norway.
    Retterstöl N
    Behav Neuropsychiatry; 1973 Oct-1974 Mar; 5(7-12):18-23. PubMed ID: 4154739
    [No Abstract]   [Full Text] [Related]  

  • 39. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Characterisation and prevalence of the psychological and behavioural symptoms in patients with dementia].
    López-Pousa S; Vilalta-Franch J; Garre-Olmo J; Pons S; Cucurella MG
    Rev Neurol; 2007 Dec 1-15; 45(11):683-8. PubMed ID: 18050101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.